Central nervous system mesenchymal chondrosarcoma

Maurizio Salvati, E. Caroli, A. Frati, M. Piccirilli, A. Agrillo, C. Brogna, G. Occhiogrosso, F. Giangaspero

Research output: Contribution to journalArticle


Central nervous system mesenchymal chondrosarcomas are rare malignant tumors that constitute a separate entity from the classical chondrosarcoma and myxoid variant. Clinical behaviour of central nervous system chondrosarcomas is still unknown. We describe two rare examples of intracranial mesenchymal chondrosarcoma with a review of the literature, in an attempt to clarify the clinical characteristics, prognosis and treatment of choice of these unusual tumors. Among the 55 reported cases, 23 had postoperative radiotherapy. Although there is no statistical significance according to the Log-Rank test (p=0.7), the patients treated with radiation therapy seem to have a better chance of survival. Patients who had adjuvant chemotherapy (only 5) showed survival times similar to those patients who had none. Although clinical behaviour of central nervous system chondrosarcomas remains to be defined, data from our series as well as literature show that radical removal is the best therapeutic choice. In addition, patients treated with postoperative radiotherapy seem to show a trend toward increased survival.

Original languageEnglish
Pages (from-to)317-324
Number of pages8
JournalJournal of Experimental and Clinical Cancer Research
Issue number2
Publication statusPublished - Jun 2005


  • Chondrosarcomas
  • Intracranial cartilaginous tumor
  • Meningeal tumors
  • Mesenchymal chondrosarcoma
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Central nervous system mesenchymal chondrosarcoma'. Together they form a unique fingerprint.

  • Cite this

    Salvati, M., Caroli, E., Frati, A., Piccirilli, M., Agrillo, A., Brogna, C., Occhiogrosso, G., & Giangaspero, F. (2005). Central nervous system mesenchymal chondrosarcoma. Journal of Experimental and Clinical Cancer Research, 24(2), 317-324.